FDA approves Rituxan biosimilar

(By Alia Paavola for Becker’s Hospital Review)

The FDA has approved Pfizer’s biosimilar to Rituxan, a treatment for some cancers and autoimmune diseases.  Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.